About Heart Failure with Preserved Ejection Fraction (HFpEF) Heart failure (HF) is a global pandemic with an estimated 64.3 million cases worldwide and a rising prevalence trend.

This Phase 1/2a clinical trial evaluates the first-in-human cardiac gene therapy candidate SRD-002 for the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF).

VS-041 inhibits specific MMPs that contribute to the pathophysiology of heart failure with preserved ejection fraction (HFpEF)," said Noreen Henig, MD, Chief Medical Officer of Vasa Therapeutics.

FRIDAY, May 30, 2025 (HealthDay News) — Dr. Robert Jarvik, the man behind the world’s first permanent artificial heart used in a human, has died. He was 79, The New York Times reported.

Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per year. Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of ...

Following the recommendation of the Data Safety Monitoring Board (DSMB), dosing has begun for patients in Cohort B (high-dose). This Phase 1/2a clinical trial evaluates the first-in-human cardiac gene ...